Skip to main content

Table 2 Diagnosis and treatment

From: Value of transfusion independence in severe aplastic anemia from patients’ perspectives – a discrete choice experiment

 

All Respondents (N = 30)

First Diagnosed with SAA, N (%)

 2 or fewer years ago

15

(50.0%)

 3 to 4 years ago

8

(26.7%)

 5 or more years ago

7

(23.3%)

Symptoms and Complications,a N (%)

 Fatigue (interferes with daily activities like work and school)

26

(86.7%)

 Infections requiring hospitalization

16

(53.3%)

 Bleeding

16

(53.3%)

Number of Treatments Received after SAA Diagnosis, N (%)

 1–3

13

(43.3%)

 4–5

10

(33.3%)

 6 or more

7

(23.3%)

Types of Treatments Received after SAA Diagnosis,a N (%)

 Immunosuppressive therapies

29

(96.7%)

 Steroids

24

(80.0%)

 Targeted therapy

17

(56.7%)

 Antibiotics

17

(56.7%)

 Antifungals

14

(46.7%)

 Bone marrow transplant

10

(33.3%)

 Erythropoiesis-stimulating agents/growth factors

9

(30.0%)

Red Blood Cell or Whole Blood Transfusions Frequency, N (%)

 Have not received red blood cell transfusions in the past 3 months

16

(53.3%)

 Once every 31–90 days

4

(13.3%)

 Once every 15–30 days

5

(16.7%)

 Once every 8–14 days

5

(16.7%)

 Once per week

0

(0.0%)

 More than once per week

0

(0.0%)

Platelet Transfusions Frequency, N (%)

 Have not received platelet transfusions in the past 3 months

21

(70.0%)

 Once every 31–90 days

3

(10.0%)

 Once every 15–30 days

1

(3.3%)

 Once every 8–14 days

2

(6.7%)

 Once per week

3

(10.0%)

 More than once per week

0

(0.0%)

Received Iron Chelation Therapy, N (%)

11

(36.7%)

  1. aRespondents were allowed to select multiple values for symptoms and complications, and treatments received, thus counts and percentages may sum to more than the total N or 100%